<DOC>
	<DOCNO>NCT02954042</DOCNO>
	<brief_summary>The purpose investigation compare clinical benefit use Pelvital product , comparison sham procedure noninvasive treatment female incontinence</brief_summary>
	<brief_title>Pelvital Stress Urinary Incontinence Training Device : P-SUIT</brief_title>
	<detailed_description>120 subject SUI recruit randomize , double-blind , sham-controlled crossover trial . Subjects allocate 1:1 ratio ( 60 per arm ) either control arm ( PFMT ) treatment arm ( PFMT conjunction Pelvital therapy ) . Subjects conduct respective therapy five minute day course six week . At week two , four six , subject conduct bi-weekly check-ups . After six week , patient control arm option cross treatment arm improvement symptom show .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>1. female gender , 2. age 1870 , 3. clinical assessment qualify medical professional diagnosis genuine stress urinary incontinence diverse origin condition , 4. minimum ten gram increase initial 24hour pad weight test 5. previous surgery pelvic region , 6. ability contract pelvic floor muscle appropriately adequate training , 7. must able agree document incontinence , void fluid intake daily void diary 8. voluntary participation signing informed consent form 1. diagnose mixed urge urinary incontinence , 2. previous surgery pelvic region , 3. unable contract pelvic floor , 4. impaired cognitive function 5. physical limitation impede patient 's ability participate ( e.g. , ability stand conduct physical demand test protocol ) , 6. acute severe infection ( e.g. , pneumonia ) , 7. neurologic condition ( e.g. , stroke , epilepsy , Parkinson disease , multiple sclerosis ) , 8. random blood sugar 10 mmol/L , 9. pregnant actively try conceive , 10. pelvic gynecological surgery le 3 week next 8 week , 11. previous treatment biofeedback similar device , 12. history pelvic irradiation , 13. concurrent medication Î±adrenergic antagonist ( e.g. , terazosin , tamsulosin , doxazosin ) , diuretic , serotoninnoripinephrine reuptake inhibitor medication know worsen incontinence , 14. stage III IV pelvic organ prolapse accord Pelvic Organ Prolapse Quantification System , 15. severe urethral sphincter weakness and/or defect , 16. suspect urethral and/or vesical fistula , 17. urinary tract infection hematuria .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Incontinence</keyword>
</DOC>